News
Obsidian Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference 2022
September 6, 2022
Read More
MD Anderson and Obsidian Therapeutics announce FDA Clearance of IND application for novel TIL therapy OBX-115
July 21, 2022
Read More
Obsidian Therapeutics to Participate in a Panel at William Blair Biotech Focus Conference 2022
July 11, 2022
Read More
ABOUT US
We are pioneers in cell and gene therapy
Leading the next generation of engineered therapeutics
Our Platform
Our proprietary
cytoDRiVE platform
Leverages drug responsive domains (DRDs) to control protein function using an FDA-approved small molecule
OBSIDIAN CAREERS
Join Our Team
Join our collaborative team of innovators who are motivated by a sense of urgency to help patients in need.
Our collective knowledge, capabilities, intellect and energy is our greatest strength.